Jacques Zimmer studied Medicine in Strasbourg (France) where he obtained his MD degree. After a few years of clinical work, he started a PhD thesis at the University of Strasbourg (Laboratory of Daniel Hanau (MD, DSc) and Henri de la Salle (PhD) about Natural Killer (NK) cells in human transporter associated with antigen processing (TAP) deficiency. After his PhD degree, he spent 3.5 years as a postdoctoral fellow in the Laboratory of Prof. Werner Held (PhD) at the Ludwig Institute for Cancer Research in Lausanne (Switzerland), where he investigated NK cell education and brought up, together with his colleagues, the cis interaction model of NK cell education.From October 2003 to November 2024, Dr. Zimmer was a Senior Research Scientist in Translational Immunology at the Department of Infection and Immunity (Director: Prof. Dr. med. Markus Ollert) of the Luxembourg Institute of Health (LIH), located in Esch-sur-Alzette (Luxembourg). He obtained his Habilitation in 2006, with Prof Jules A. Hoffmann, Nobel Prize Winner in 2011, as President of the jury.From 2014 to 2024, Dr. Zimmer taught immunology to Third Year Bachelor students in Life Sciences at the University of Luxembourg (UNI.lu). From 2022 to 2024, he was responsible for the organization and management of bio-clinical lectures in Hematology and Immunology in the 5th Semester of the Bachelor of Medicine at the UNI.lu.His research data, reviews and editorials, mostly dedicated to NK cells, have been published in numerous international peer reviewed journals. The publication count of Dr. Zimmer is currently at 113 contributions, with his work cited 4729 times and with an H-factor of 36 (Scopus, January 10th, 2025).He supervised or co-supervised 7 PhD theses, which were all successfully finished.Dr. Zimmer regularly reviews international manuscripts and grant applications, and he edited the first edition of the present NK cell book in 2010.Evelyn Ullrich, MD, is Professor of Cellular Immunology and head of the unit “Experimental Immunology and Cell Therapy” at Johann Wolfgang Goethe University in Frankfurt, Germany. She completed her clinical and research training in Freiburg, Erlangen and Paris and is a specialist in internal medicine and immunology. The current research of her group addresses the development of engineered personalized immune cell therapy with focus on NK cells.Currently, Evelyn Ullrich is speaker of the study group “NK cells & ILCs” of the German Society for Immunology (DgfI e.V.). She is an internationally recognized expert in this field, author, reviewer and editor of specialist journals and spokesperson of NK cell consortia funded by the German Cancer Research Center (DKTK) and as part of the Priority and Drug Development Program supported by the German Cancer Aid (Stiftung Deutsche Krebshilfe).Furthermore, she is speaker of a German Research Foundation (DFG)-funded Clinician Scientist program and the Mildred Scheel Career Center (MSNZ) in Frankfurt, which is an excellence program for promoting young scientists in cancer research.
